skip to Main Content

Welcome

Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Changes To E/M Codes Beginning On January 1st

Effective January 1, 2021, the Centers for Medicare & Medicaid (CMS) finalized significant changes to…

read more

Additional COVID-19 Relief Up in the Air

House Speaker Nancy Pelosi (D-CA) and Treasury Secretary Steven Mnuchin appeared to be moving closer…

read more

CY 2021 Physician Fee Schedule Proposed Rule Summary

On August 3, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

04/01/21: Fellow Exam Application Deadline
Learn more

06/01/21: Research Grant Cycle
Learn more

06/26/21: Membership Application Deadline to be eligible for AAOA Member rate for the 2021 Basic Course

08/01/21: Scientific Abstract Submission Deadline
Learn More

09/01/21: Membership Application Deadline to be voted in at the 2021 Annual Meeting

12/01/21: Research Grant Cycle
Learn more

EDUCATION

Our 2021 AAOA Basic Course in Allergy & Immunology will be launched June 1st: Over 11 hrs of pre-learning, on-demand will set you up to gain the full value of our curriculum and engage in the live-stream session.

Live Stream July 8-11 will offer unique learning formats to offer learners the core concepts of allergy diagnosis and management. Join us and test your pre-work efforts for our Immunology & Pharmacotheapy Trivia Slams; Great Debates on Environmental Controls; Allergen Testing Panel “Bake Off,” Late Night with Dr. Levy, AAOA’s Escape Room Expedition, Hands On Testing and Dose Calculation Practica, Office Tours, and more.

Structured for otolaryngologists integrating more allergy assessment and management into their practice, AAOA members providing specialized allergy care who need to remain current with literature-based evidence and practice trends, residents, PA/NPs who work in otolaryngology, and allied health staff who support their physicians in the management of allergic patients. The Basic Course offers unique opportunities to learn the state of the art in allergy patient care. Learn More

IFAR

Available Now

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2021 Basic Course in Allergy & Immunology
On-demand June 1; Live Stream July 8-11 | Virtual
Learn More and Register

2021 AAOA Annual Meeting
Pre-launch Mid-September
Live Stream Starting on Oct 16 | Virtual
Learn More

2022 AAOA Advanced Course
In-Person!!! Santa Fe, MN
January 13-15, 2022
Learn More

USP 797 Online Module
Learn More and Register

News and Updates

2021 ICARS Rhinosinusitis: What You Need To Know

June 24th, 8pm EDT REGISTER The 2021 update of ICAR: Rhinosinusitis has been recently published…

read more

Targeted Molecular Therapies in Allergy and Rhinology

AAOA's "Targeted Molecular Therapies in Allergy and Rhinology” (Damask C. et al) was published in…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

Earn CME Credit in Upcoming Activity Titled: The Role Of Biologics for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Release Date: August 14, 2020; Expiration Date: August 13, 2021

Nasal polyps impact an estimated 13 million Americans. In particular, nasal polyps affect 45% of people with adult-onset asthma and approximately 30% of people with chronic rhinosinusitis, in the latter, it is known as chronic rhinosinusitis with nasal polyps (CRSwNP). The heterogeneity of CRSwNP may explain the recurrence of nasal polyps and the limitations of a “one size fits all” medical and surgical approach for the treatment for CRSwNP. The development of biologics targeting various aspects of chronic inflammation for the treatment of CRSwNP is evolving rapidly. This program discusses the prevalence and underlying pathophysiology of CRSwNP and the clinical trial data on emerging therapeutics options based on their mechanisms of action, efficacy, and safety data. 

Target Audience

This initiative is intended for otolaryngologists (ENTs) interested in better understanding the role of biologics in reducing inflammation and related symptomatology in ENT disorders, especially nasal polyposis.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Describe the prevalence and underlying pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Review the emerging biologic targets and treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Evaluate the clinical trial data on emerging therapeutics options for chronic rhinosinusitis with nasal polyps (CRSwNP) based on their mechanisms of action, efficacy, and safety data

Accreditation

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Criteria for Success

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

For more information and to participate in the activity please http://aaoacme.org/

Back To Top